tough times ahead for dndn, page-7

Thanks for your posts Eagle and Wisdom...

just a reminder for holders or those looking at investing in PRR ...

from the PRR website ...

" Prima BioMed’s leading drug, CVac™ targets cancer cells expressing mucin-1 which are prolific on the surface of many cancers.

Mucin-1 protein is not only common in ovarian cancer; it is also expressed in prostate, kidney, pancreatic, breast, colon, and lung cancer cells.

This significantly opens the market for CVac™ to be applied to a variety of cancer types which is unique compared to other drug discovery and development companies. "


the link
http://www.primabiomed.com.au/trial/faq.php

... what this means is that if indeed Cvac is ' commercialised ' as such .... the target / forward revenue estimates are for tackling only 10 % of the Ovarian Cancer market .... and if the door is then openeed to indeed become a therapy to tackle other mucin - 1 expressing cancers ... the revenues will be far in excess of those stated ...